Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

An Open-Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as Well as in Specified Risk Groups

Authors not listed

Alachua Government Services, Inc. · 2008

Abstract

The purpose of this study is to assess the safety and tolerability of, and the immune response to a non-adjuvanted H5N1 influenza vaccine in an adult and elderly population and in specified risk groups. Furthermore, persistence of H5N1 influenza antibodies after vaccination with this vaccine will be assessed.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-25 MST

Cite this

APA
Anonymous. (2008). An Open-Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as Well as in Specified Risk Groups. <em>Alachua Government Services, Inc.</em>. https://clinicaltrials.gov/study/NCT00711295
Vancouver
Anonymous. An Open-Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as Well as in Specified Risk Groups. Alachua Government Services, Inc.. 2008.
BibTeX
@misc{anon2008AnOpen, title = {An Open-Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as Well as in Specified Risk Groups}, author = {Anonymous}, journal = {Alachua Government Services, Inc.}, year = {2008}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings